Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21795656 | 0.85 | SLC6A3 (0.47) | SLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL21795655 | 0.85 | SLC6A3 (0.47) | SLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL9546969 | 0.74 | LMNA (0.62) | GAAALDH1A1LMNARECQL | |
| SCHEMBL9547063 | 0.74 | LMNA (0.62) | GAAALDH1A1LMNARECQL | |
| SCHEMBL6719058 | 0.69 | RECQL (0.54) | GAAL3MBTL1LMNARECQL | |
| SCHEMBL3058008 | 0.69 | GAA (0.57) | GAAL3MBTL1LMNARECQL | |
| SCHEMBL3052941 | 0.69 | GAA (0.57) | GAAL3MBTL1LMNARECQL | |
| SCHEMBL6517000 | 0.69 | GAA (0.57) | GAAL3MBTL1LMNARECQL | |
| Hydrochloric Acid SCHEMBL6527528 | 0.68 | GAA (0.55) | GAAL3MBTL1LMNARECQL | |
| SCHEMBL30672700 | 0.68 | GAA (0.44) | GAAL3MBTL1LMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | SLC6A3 17/4885SLC6A4 10/4885GAA 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.